{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:17:52Z","timestamp":1770711472268,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13730-020-00463-z","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T15:02:21Z","timestamp":1584543741000},"page":"237-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy"],"prefix":"10.1007","volume":"9","author":[{"given":"Homare","family":"Shimohata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ohgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Takayasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"463_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","volume":"167","author":"JA Kint","year":"1970","unstructured":"Kint JA. Fabry\u2019s disease: alpha-galactosidase deficiency. Science. 1970;167:1268\u20139.","journal-title":"Science"},{"key":"463_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22:843\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"463_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/gim.2018.31","volume":"21","author":"H Maruyama","year":"2019","unstructured":"Maruyama H, Miyata K, Mikame M, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinic for genetic analysis. Genet Med. 2019;21:44\u201352.","journal-title":"Genet Med"},{"key":"463_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet. 2015;52:860\u20136.","journal-title":"J Med Genet"},{"key":"463_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C Tondel","year":"2013","unstructured":"Tondel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137\u201348.","journal-title":"J Am Soc Nephrol"},{"key":"463_CR6","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2215\/CJN.01820217","volume":"12","author":"R Skrunes","year":"2017","unstructured":"Skrunes R, Tondel C, Leh S, et al. Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease. Clin J Am Soc Nephrol. 2017;12:1470\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"463_CR7","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.2169\/internalmedicine.55.7367","volume":"55","author":"H Shimohata","year":"2016","unstructured":"Shimohata H, Ogawa Y, Maruyama H, Hirayama K, Kobayashi M. A case of renal variant of Fabry disease diagnosed by the presence of urinary mulberry cells. Intern Med. 2016;55:3475\u20138.","journal-title":"Intern Med"},{"key":"463_CR8","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","volume":"25","author":"AB Fogo","year":"2010","unstructured":"Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010;25:2168\u201377.","journal-title":"Nephrol Dial Transplant"},{"key":"463_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s13730-017-0262-5","volume":"6","author":"H Shimohata","year":"2017","unstructured":"Shimohata H, Maruyama H, Miyamoto Y, Takayasu M, Hirayama K, Kobayashi M. Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry disease. CEN Case Rep. 2017;6:148\u201351.","journal-title":"CEN Case Rep"},{"key":"463_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 53 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"463_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","volume":"3","author":"M Beck","year":"2015","unstructured":"Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry outcome survey analysis. Mol Genet Metab Rep. 2015;3:21\u20137.","journal-title":"Mol Genet Metab Rep"},{"key":"463_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s10157-015-1146-7","volume":"20","author":"O Saito","year":"2016","unstructured":"Saito O, Kusano E, Akimoto T, et al. Prevalence of Fabry disease in dialysis patients: Japanese Fabry disease screening study (J-FAST). Clin Exp Nephrol. 2016;20:284\u201393.","journal-title":"Clin Exp Nephrol"},{"key":"463_CR13","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28:1631\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"463_CR14","first-page":"9","volume":"2","author":"T Nakamichi","year":"2013","unstructured":"Nakamichi T, Miyazaki M, Nakayama K, et al. Fabry\u2019s disease discovered with chance urinary mulberry cells: a case report. CEN Case Rep. 2013;2(4):9\u201352.","journal-title":"CEN Case Rep"},{"key":"463_CR15","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.2169\/internalmedicine.55.7084","volume":"55","author":"T Honda","year":"2016","unstructured":"Honda T, Komatsu E, Furuse S, Mise N. Fabry disease diagnosed based on the detection of urinary mulberry bodies. Intern Med. 2016;55:2903.","journal-title":"Intern Med"},{"key":"463_CR16","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2169\/internalmedicine.1177-18","volume":"57","author":"R Onishi","year":"2018","unstructured":"Onishi R, Kanaoka K, Sugiura J, et al. A cardiac variant of Fabry disease diagnosed with chance urinary mulberry cells. Intern Med. 2018;57:2285\u20138.","journal-title":"Intern Med"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-020-00463-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T01:01:48Z","timestamp":1616029308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-020-00463-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00463-z","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]},"assertion":[{"value":"2 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patients for their cases to be reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}